Descrizione del progetto
Biomarcatori a microRNA per l’ipertensione
L’ipertensione è la principale causa di malattie cardiovascolari e colpisce quasi un terzo della popolazione adulta del mondo. Con diagnosi e terapie rimaste invariate per anni, gli scienziati del progetto MITO, finanziato dall’UE, stanno studiando nuovi metodi per migliorare l’assistenza sanitaria dei pazienti ipertesi. Il lavoro si concentrerà sulla scoperta di microRNA mitocondriali nel sangue di soggetti con ipertensione. Queste piccole molecole di regolazione costituiscono una fonte accessibile di biomarcatori e sono state ampiamente utilizzate come bersagli terapeutici in applicazioni cliniche. I ricercatori sono anche interessati a studiare il ruolo dei microRNA nello sviluppo dell’ipertensione, spianando la strada alla scoperta di nuove terapie antiipertensive.
Obiettivo
Hypertension is an extreme public health problem affecting nearly one third of the World’s adult population. Most cardiovascular diseases are provoked by hypertension resulting in an estimated 9.4 million deaths every year. Surprisingly, the diagnosis of hypertension has changed very little over the past 100 years - just using a stethoscope definitely needs refining. Furthermore, the epidemic proportion of hypertension worldwide pinpoints the necessity for the discovery of fresh antihypertensive therapies. Thus the main objective of the MITO project is to discover novel methods to improve healthcare of hypertension patients. For this we will investigate the circulating pool of microRNAs (small RNA molecules present in the blood, regulating gene expression) - we hypothesize that particularly mitochondrial microRNAs play a critical role in hypertension development. Easily obtainable in the blood, microRNAs constitute an accessible source of biomarkers and therapeutic targets for clinical application. The research plan envisages three scientific work packages dedicated (1) to the discovery of candidate microRNAs associated with hypertension by using small RNA sequencing in 30 hypertensive patients and 30 controls, (2) the validation of candidate microRNAs in a group of 540 participants (paying attention to sex specificities), and (3) to the functional assessment of the role of microRNAs in hypertension development. While the first two parts of the project will be conducted at the host institution in Luxembourg, functional studies will involve three secondments to partner institutions in Denmark, Germany, and France. A successful outcome will have implications ranging from contributing to satisfy the need for novel methods to stop the progression of hypertension, to a better understanding of the role of microRNAs in hypertension development, to the training of a young East European researcher to pioneer development in a research field just emerging in her home country.
Campo scientifico
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinatore
1445 Strassen
Lussemburgo